eligibility_summary
Adults (≥18) with histologically confirmed large B‑cell lymphoma, relapsed/refractory after ≥2 prior lines incl. auto‑HSCT and anthracycline+rituximab/CD20, PET+ and measurable CT+ per Lugano, ECOG 0–1, adequate organs and leukapheresis access, CD19+ if previously CD19‑treated, contraception for 1 yr. Excludes CNS‑only/primary CNS, other cancer not in ≥2‑yr remission, active infections (HBV/HCV/HIV/syphilis), recent/active DVT/PE, GVHD, serious CV/CNS disease, pregnancy, recent therapy w/o washout, prior CAR‑T/GM T cells.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06149169: Single-arm Phase 2 study in China evaluating relmacabtagene autoleucel (relma‑cel/JWCAR029), an autologous CD19‑targeted chimeric antigen receptor (CAR) T‑cell therapy, dosed at 1×10^8 CAR+ T cells, for relapsed/refractory large B‑cell lymphoma. Mechanism: patient T cells are genetically engineered to express a CAR that binds CD19 on B cells, triggering MHC‑independent T‑cell activation, proliferation, cytokine release, and cytotoxic killing of CD19+ malignant cells, expected on‑target B‑cell aplasia. Targets: CD19 on B cells, engages T‑cell activation/cytolytic pathways.